administration of breakthrough cancer pain in people who are already obtaining opioid medication for underlying, persistent painCOVID?19 might have disrupted data selection and analysis starting in 2020. There have also been fewer retail?amount undercover drug buys reported in STRIDE/STARLIMS recently, restricting assessment of adjustments in costs